Rumors flying on Geron, ACT, CIRM and the stem cell field
Geron abruptly announced today that it will no longer pursue its spinal cord injury trial using oligodendrocyte precursor cells (OPCs) derived from hESC. Several sources indicate that Geron is hoping to find a buyer of its drug for this trial, GRNOPC1 and the hope is that the trial could be rescued in a sense. Why […]
Rumors flying on Geron, ACT, CIRM and the stem cell field Read More »